Passage Bio (PASG) Granted FDA Fast Track for 3 Gene Therapy Candidates

 Passage Bio, Inc. (Nasdaq: PASG) announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s three lead investigational gene therapies: PBGM01 for the treatment of GM1 gangliosidosis (GM1), PBFT02 for frontotemporal dementia with granulin mutations (FTD-GRN), and PBKR03 for Krabbe disease. Passage Bio plans to initiate clinical trials in GM1 in the first quarter of 2021 and in FTD-GRN and Krabbe disease in the first half of 2021.

https://www.streetinsider.com/Corporate+News/Passage+Bio+%28PASG%29+Granted+FDA+Fast+Track+Designation+for+Three+Gene+Therapy+Candidates+Targeting+Rare+CNS+Disorders/18092519.html